Molecular diagnostics

$130+ Billion In-Vitro Diagnostics Markets - Global Forecast to 2030: AI and Machine Learning Revolutionize Molecular Diagnostics in In-Vitro Diagnostics Industry - ResearchAndMarkets.com

Retrieved on: 
Monday, August 21, 2023
Health, Technology, Other Technology, Health Technology, Artificial Intelligence, Biotechnology, Prevalence, Lab, Infection, NGS, COVID-19, Molecular diagnostics, Genomics, Proteomics, Government, Hospital, Immunoassay, IVD, Hospital Clinic Manuel Quintela, Growth, Conditional sentence, Diagnosis, POC, PCR, Kits, Medical device, Software, Biochemistry

The global in vitro diagnostics market is expected to register a CAGR of 4.6% from 2023 to 2030 to reach $130.1 billion by 2030.

Key Points: 
  • The global in vitro diagnostics market is expected to register a CAGR of 4.6% from 2023 to 2030 to reach $130.1 billion by 2030.
  • Moreover, the inclination of emerging economies toward personalized medicine and advancements in genomics & proteomics offer significant growth opportunities for the players operating in this market.
  • Based on the technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the market.
  • Based on end user, the hospitals & clinics segment is expected to grow with the highest CAGR during the forecast period.

QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook

Retrieved on: 
Tuesday, August 8, 2023
QIAGEN, QGEN, Table, CER, COVID-19, Tax, Original equipment manufacturer, GAAP, Molecular diagnostics, COVID, COVID-19 testing, Huntingdon Life Sciences, Forecasting, Public expenditure, EBITDA, Investment, Plant, Growth, EPS, OEM, PDF, NYSE, QuantiFERON, Pharmaceutical industry

Net sales results of $497 million at constant exchange rates (CER) for Q2 2023 were above the outlook for at least $490 million CER, driven by 9% CER growth in the non-COVID-19 portfolio.

Key Points: 
  • Net sales results of $497 million at constant exchange rates (CER) for Q2 2023 were above the outlook for at least $490 million CER, driven by 9% CER growth in the non-COVID-19 portfolio.
  • Overall sales results for Q2 2023 declined 4% (-4% CER) to $495 million from Q2 2022, a period marked by significant COVID-19 sales.
  • Adjusted diluted earnings per share (EPS) were $0.51, and results of $0.52 CER were above the outlook for at least $0.50 CER.
  • “Our teams at QIAGEN exceeded the outlook we set for both sales and profitability in the second quarter of 2023," said Thierry Bernard, Chief Executive Officer of QIAGEN.

City of Hope scientists develop targeted chemotherapy able to kill all solid tumors in preclinical research

Retrieved on: 
Tuesday, August 1, 2023
Linda, Molecule, Alex's Lemonade Stand Foundation, DNA, Rituximab, Insulin, Human, City of Hope National Medical Center, City of Hope, R01, Neoplasm, Biotechnology, Cell Chemical Biology, Trastuzumab, Clinical trial, Ovary, Breast, Toxicity, Brain, Research, Gene expression, Prostate, Treatment of lung cancer, Cell, Molecular diagnostics, Translational Genomics Research Institute, Cetuximab, Experiment, RLL, Bangladesh Technical Education Board, DNA replication, National Cancer Institute, S phase, Australian Melanoma Research Foundation, Patient, Department of Defense Serum Repository, Apoptosis, LOS, Beckman Research Institute, Proliferating cell nuclear antigen, Therapy, Skin, PCNA, Vaccine, Pharmaceutical industry, Molecular oncology, City, Hope

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research. As the scientists continue to investigate the foundational mechanisms that make this cancer-stopping pill work in animal models, they note that there is an ongoing Phase 1 clinical trial testing the City of Hope-developed therapeutic in humans.

Key Points: 
  • Data suggests PCNA is uniquely altered in cancer cells, and this fact allowed us to design a drug that targeted only the form of PCNA in cancer cells.
  • The investigational chemotherapeutic is currently in a Phase 1 clinical trial in humans at City of Hope."
  • Now that we know the problem area and can inhibit it, we will dig deeper to understand the process to develop more personalized, targeted cancer medicines."
  • "City of Hope has world leaders in cancer research.

Global Next-Generation Diagnostics Market Trends & Growth Projections to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 21, 2023
Science, Health, Clinical Trials, Research, Universe, Clinical chemistry, COVID-19, Liquid biopsy, Molecular diagnostics, Infection, Genomics, POCT, Traction, GDP, Patient, Laboratory, Physician, Strategy, Mergers and acquisitions, IVD, Growth, AI, Multisystem inflammatory syndrome in children, Environment, Automation, Medical device, Retail, Marketing, Immunoassay

As COVID-19 transitions to the endemic phase, automation solutions and smart, connected laboratories will catalyze recovery in the next-generation diagnostics industry.

Key Points: 
  • As COVID-19 transitions to the endemic phase, automation solutions and smart, connected laboratories will catalyze recovery in the next-generation diagnostics industry.
  • The study examines next-generation diagnostics market trends and growth projections to 2028 across different geographical regions, innovative in vitro diagnostics technologies and applications, major vendors to watch, and growth opportunities in the post-pandemic future.
  • The report on next-generation diagnostics industry covers a range of key topics, providing insights into growth opportunities, revenue trends, mergers and acquisitions, predictions for 2023, and market snapshots for specific segments.
  • The Growth Environment section explores market segmentation and the overall growth environment for the next-generation diagnostics market.

Molecular Loop Appoints Paul Brown, Ph.D. to its Board of Directors

Retrieved on: 
Tuesday, May 16, 2023
Union of Sales and Marketing Professionals, Doctor of Philosophy, Life cycle, Virology, Roche, Molecular diagnostics, Infection, Genomics, Marketing, Laboratory, Genetic testing, Growth, Microbiology, Pharmaceutical industry, Fine chemical, California Institute of Technology

WOBURN, Mass., May 16, 2023 /PRNewswire/ -- Molecular Loop Biosciences, Inc., a leader in targeted sequencing, is pleased to announce that genomics and molecular diagnostics industry veteran Paul Brown, Ph.D. has been appointed to its board of directors.

Key Points: 
  • WOBURN, Mass., May 16, 2023 /PRNewswire/ -- Molecular Loop Biosciences, Inc., a leader in targeted sequencing, is pleased to announce that genomics and molecular diagnostics industry veteran Paul Brown, Ph.D. has been appointed to its board of directors.
  • "We look forward to working with Dr. Brown to achieve our mission of making genetic testing more accessible"
    "We are excited to have Paul join our board of directors and bring his extensive expertise in the genomics and molecular diagnostics industries to Molecular Loop.
  • In 2010, Dr. Brown transitioned to Roche's Diagnostics Division as President and CEO of Roche Molecular Diagnostics.
  • Before retiring from Roche at the end of 2020, Dr. Brown was Head of Roche Molecular Solutions, responsible for the company's Molecular Diagnostics, Tissue Diagnostics, and Sequencing Solutions Business Units worldwide.

Labroots Hosts its 11th Annual Genetics Week Online Event, on May 16-18, 2023

Retrieved on: 
Thursday, May 11, 2023
Networking hardware, Senior, Molina Healthcare, Liquid biopsy, Utah Tech University, Molecular diagnostics, Doctor of Philosophy, Science, STI, Gastroenteritis, Patient, Risk, Trend News Agency, Policy, Environment, Virus, News, SCS, Informatics, Impact, Culture, Mutation, PMC, Research, Lung cancer, Bacteria, CDX, Conference, CEU, Infection, Cancer, SOC, Senior counsel, Continuing education, Standard of care, Science policy, Parasitism, Labroots, MPH, NSGC, Scale, Genetic variation, Q&A, All, Personalized medicine, Harvard Medical School, Implementation, Physician, Health, Elective genetic and genomic testing, Nursing, Vaccine, Medical imaging, Management, Genomics, Genetics, MD, Pharmacy, Medicine

YORBA LINDA, Calif., May 11, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website, offering premier interactive virtual events and webinars, today announced its 11th annual Genetics Week virtual event scheduled on May 16-18, 2023. This premier scientific conference focused on advancing the frontiers of science through cutting-edge research and presented by a diverse range of leading experts from academia and institutions promises to showcase the latest developments in the fields of Genetics and Genomics, Precision Medicine and Molecular Diagnostics.

Key Points: 
  • Thousands of conference attendees will be intrigued to learn more about health outcomes, novel therapies and advancements in health systems and personalized medicine today.
  • Day three concludes the Genetics Week event bringing even more thought-provoking discussions relevant to the discipline of molecular diagnostics.
  • Produced on Labroots' comprehensive platform, while connecting across all desktop and mobile devices, the interactive environment provides an immersive educational experience.
  • Use the hashtag #LRgenetics to follow the conversation and connect with other members of the global Genetics & Genomics community!

CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation

Retrieved on: 
Wednesday, April 19, 2023
Health, Surgery, Clinical Trials, Research, Cardiology, Science, Columbia University, University of Southern California, Heart, Abstract, University, FAST, Stanford University, University of Maryland, College Park, University of Maryland Medical Center, Molecular diagnostics, Vanderbilt University, Stanford University Medical Center, Assistant, Maryland School, Patient, Risk, Master of Science, University of Maryland School of Medicine, Medicine, FCCP, Hospital, CDT, Role, MPH, International Society for Heart and Lung Transplantation, International Society, University of Virginia, Caregiver, Heart transplantation, Dentistry, Food delivery, Lung transplantation, Brigham, MD, Surveillance

Challenging Cases in Post-Cardiac Transplant Care: The Role of Molecular Diagnostics in Surveillance, April 20, 11:30am, CDT.

Key Points: 
  • Challenging Cases in Post-Cardiac Transplant Care: The Role of Molecular Diagnostics in Surveillance, April 20, 11:30am, CDT.
  • Moderated by Eugene DePasquale, MD, University of Southern California and Jeremy Kobulnik, MD, CareDx.
  • Just Breathe - Facing Clinical Challenges in Lung Transplantation, April 21, 11:30am, CDT.
  • Speakers include Hannah Mannem, MD, University of Virginia; Nirmal Sharma, MD, Brigham and Women’s Hospital; and Anil Trindade, MD, Vanderbilt University.

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Awardees and Opens Spring 2023 Submissions

Retrieved on: 
Monday, April 17, 2023
Health, Other Science, General Health, Clinical Trials, Research, Science, Biotechnology, Medical laboratory, University, NGS, Fusion, Liquid biopsy, Cancer, Molecular diagnostics, Thermo Fisher Scientific, Genomics, Acute myeloid leukemia, AML, Journal, Outline, Patient, Pathology, Medicine, Memorial Sloan Kettering Cancer Center, The Journal of Molecular Diagnostics, Pharmaceutical industry, Nursing, Medical imaging, Medical device, MD

In support of global initiatives to advance molecular profiling in oncology, Thermo Fisher Scientific today announced the latest recipients of the Oncomine Clinical Research Grant and the opening of its submissions for Spring 2023.

Key Points: 
  • In support of global initiatives to advance molecular profiling in oncology, Thermo Fisher Scientific today announced the latest recipients of the Oncomine Clinical Research Grant and the opening of its submissions for Spring 2023.
  • First introduced in 2020, the Oncomine Clinical Research Grant is awarded to independent clinical research teams with financial support up to $200,000 in reagents and general funding for their studies.
  • Oncomine Grants are available for clinical research projects focusing on molecular testing in oncology and reproductive health.
  • For more information on the Oncomine Clinical Research Grant Program and how to submit proposals, please visit www.oncomine.com/grants .

QuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, February 15, 2023
Science, Biotechnology, Research, General Health, Health, Medical Devices, Data Management, Technology, EPS, QuidelOrtho, Ortho, Transfusion medicine, Molecular diagnostics, Interest, Business analyst, EBITDA, GAAP, Webcast, Point of care, Growth, Labs, Conference, Video game, Online shopping

GAAP diluted earnings per share (EPS) for the fourth quarter of 2022 decreased to $0.45, compared to $6.85 for the fourth quarter of 2021.

Key Points: 
  • GAAP diluted earnings per share (EPS) for the fourth quarter of 2022 decreased to $0.45, compared to $6.85 for the fourth quarter of 2021.
  • GAAP operating income for the fourth quarter of 2022 was $86.5 million, compared to $376.7 million for the fourth quarter of 2021, and GAAP operating margin was 10% and 59% for the fourth quarters of 2022 and 2021, respectively.
  • Adjusted diluted EPS for the fourth quarter of 2022 decreased to $1.76, compared to $5.12 for the fourth quarter of 2021.
  • Adjusted EBITDA margin for the fourth quarter of 2022 was 28.3%, compared to 45.6% for the fourth quarter of 2021.

QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

Retrieved on: 
Tuesday, February 7, 2023
Health, Technology, Other Science, Software, Science, Pharmaceutical, Biotechnology, CER, Public expenditure, EPS, Molecular diagnostics, QIAGEN, NYSE, Plant, Acquisition, EBITDA, Table, GAAP, Forecasting, QGEN, Growth, PDF, COVID-19, Tax, Video game, Pharmaceutical industry, Insight

Sales at CER were $531 million, a decline of 9% and above the outlook for at least $520 million CER.

Key Points: 
  • Sales at CER were $531 million, a decline of 9% and above the outlook for at least $520 million CER.
  • Adjusted diluted earnings per share (EPS) were $0.53 ($0.55 CER), and ahead of the outlook for at least $0.50 CER.
  • QIAGEN has initiated its full-year 2023 outlook for net sales of at least $2.05 billion CER and adjusted diluted EPS of at least $2.10 CER.
  • This is based on expectations for ongoing double-digit CER growth in the non-COVID product groups, while expecting a decline in COVID-19 product group sales.